Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 25, 2019 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 26,270 | -- | 68,730 | |
| Jan 02, 2021 | Director, Chief Operating Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 26,908 | $23.09 | 320,307 | |
| Feb 03, 2009 | VP, Medical Affairs | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 27,000 | -- | 27,000 | |
| Jul 25, 2007 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 27,244 | $11.50 | 197,015 | |
| Jul 25, 2007 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 27,244 | $11.50 | 197,015 | |
| Jan 04, 2021 | Chief People Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 27,369 | -- | 157,506 | |
| Jan 03, 2018 | Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 27,511 | -- | 91,695 | |
| Jan 03, 2018 | General Counsel & Corp. Secy | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4/A | 27,511 | -- | 84,574 | |
| Jan 03, 2018 | General Counsel & Corp. Secy | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 27,511 | -- | 86,137 | |
| Jan 02, 2023 | Director, President & CEO | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 27,575 | $12.21 | 662,043 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.